TET 蛋白抑制剂:潜力和限制
Robert Kaplánek1, Zdeněk Kejík1, Jan Hajduch1
1BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, 252 50 Vestec, Czech Republic; Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 455/2, 128 08 Prague, Czech Republic.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 20, 2023
概括
本综述探讨了用于癌症治疗的十-十一转位 (TET) 蛋白抑制剂. 它详细介绍了它们的机制,应用和局限性,并提供了对瘤疾病新治疗策略的见解.
科学领域:
- 生物化学和分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
背景情况:
- 十-十一转位 (TET) 蛋白质是通过DNA脱甲基化对基因表达的关键调节者.
- 异常的TET蛋白活性与各种癌症的发病有关.
- 用抑制剂向TET蛋白质为瘤疾病提供了潜在的治疗途径.
研究的目的:
- 审查和分类不同类型的TET蛋白抑制剂.
- 分析这些化合物的抑制机制和潜在应用.
- 评估TET抑制在癌症治疗中的治疗策略和局限性.
主要方法:
- 对TET蛋白抑制剂现有研究的文献综述.
- 抑制机制的分析,包括竞争性和全性抑制.
- 对TET抑制剂的疗效和安全性进行临床前和临床数据的评估.
主要成果:
- 已经确定了各种类型的TET抑制剂,它们的分子标和作用模式不同.
- 在临床前癌症模型中,抑制剂通过调节表观遗传景观,显示出有希望的结果.
- 挑战包括实现特异性,管理非目标效应,理解复杂的体内功能.
结论:
- TET蛋白抑制剂为癌症治疗提供了一个有希望的,尽管复杂的策略.
- 需要进一步的研究来优化抑制剂的设计,并充分阐明其治疗潜力和局限性.
- 向抑制TET蛋白可能导致针对各种癌症的新型表观遗传疗法.
相关概念视频
Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
Hepatic Drug Clearance: Effect of Protein Binding
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...


